Aims High plasma cholesterol concentration and increased platelet activity are two major risk factors for atherosclerosis. Lovastatin, the lipophilic drug was shown to inhibit platelet aggregation whereas pravastatin, the hydrophilic drug had no such effect. Analysis of the effect of fluvastatin which is both a lipophilic and hydrophilic drug, on platelet aggregation was the goal of the present study. Methods Fluvastatin 40 mg daily was administered to 25 patients with hypercholesterolaemia for up to 24 weeks. Normal subjects acted as controls. The influence of fluvastatin on plasma lipids and on platelet aggregation and fluidity was studied. The direct effect of fluvastatin on platelets was compared with that of other statins. Results Fluvastatin therapy (40 mg day −1 for a period of 4 weeks) in hypercholesterolaemic patients resulted in a 23% and 29% reduction in plasma levels of total cholesterol and LDL-cholesterol respectively. Platelet cholesterol/phospholipids molar ratio was reduced by 26% and platelet aggregation was significantly ( P<0.02) reduced by 10% after 4 weeks of fluvastatin treatment. On continuing fluvastatin therapy for additional 20 weeks, no further decrement in plasma LDL cholesterol levels or in platelet cholesterol/phospholipid ratio were noted. However, platelet aggregation was further significantly ( P<0.01) reduced by up to 15%. Incubation of platelets with increasing concentrations of fluvastatin or lovastatin, demonstrated a dose-dependent reduction in platelet aggregation, whereas pravastatin showed no effect. This inhibitory effect of fluvastatin or lovastatin on platelet aggregation (up to 34% or 22% respectively at a concentration of 1 mg statin ml −1 ) was found both in platelet rich plasma and in washed platelet suspensions. Fluvastatin and lovastatin (but not pravastatin), seem to share similar platelet binding sites, as non labelled fluvastatin or lovastatin were able to displace [ 3 H]-labeled-fluvastatin from its binding sites on platelets. Conclusions Fluvastatin therapy reduces platelet aggregation via a dual effect which involves its in vivo hypocholesterolaemic action on platelet cholesterol content, and also a direct effect of the drug binding to the platelets. The antiatherogenicity of fluvastatin may be related, in addition to its plasma cholesterol lowering ability, to its inhibitory effect on platelet activation.
Introduction shown to reduce platelet tendency to aggregation [19] [20] [21] [22] . Statins are most potent hypocholesterolaemic agents which Atherosclerosis is a complicated process involving the interaction of plasma lipoproteins, blood platelets and arterial inhibit cellular hydroxymethyl glutaryl coenzyme A (HMGCoA) reductase, the key enzyme in cholesterol wall cells [1] [2] [3] [4] . Blood platelets have been shown to be intimately involved in atherosclerosis [5] [6] [7] . Activated biosynthesis [23, 24] . Although all statins share the inhibitory effect on HMGCoA reductase, the different formulations of platelets can affect macrophage cholesterol accumulation, and foam cells formation, by altering the uptake of low the various statins are associated with differences in their effects on macrophage foam cell formation [25] [26] [27] . density lipoprotein (LDL) by arterial wall macrophages [8] [9] [10] [11] [12] [13] [14] . Plasma LDL in turn, can activate platelets in a Administration of statins to hypercholesterolaemic patients also affects platelets function [28] . Recently, lovastatin process which involves its binding to the platelets [1, 15, 16] .
Activation of platelets occurs in hypercholesterolaemic (which is converted to its active form within the gastrointestinal tract) administration for 20 weeks to hypercholesterolpatients, as enhanced platelet responsiveness was noted when exposed to aggregatory agonists ex vivo [1, 2, 5, 17, 18] .
aemic patients was shown to decrease significantly the extent of their platelet aggregation [28] . We thus hypothesized that the relatively new active drug fluvastatin can similarly affect analyze the effect of another new statin, fluvastatin, which amplitude in PRP and WP respectively). Platelet aggregation was performed at 37°C in a model PAP-4 computerized is an active drug, on platelet aggregation in hypercholesterolaemic patients, in relation to its effect on platelet cholesterol aggregometer using PPP or Hepes as a reference system for PRP or WP respectively [29] . In the in vitro studies, content, as well as to its binding characteristics to the platelets.
increasing concentrations of statins (0.01, 0.1, 1 and 10 mg ml −1 ) were incubated for 30 min with 1 ml of PRP Methods or WP before testing platelet aggregation. The fluvastatin salt which is hydrophilic, was dissolved in water whereas Patients the lipophilic drugs lovastatin and pravastatin were dissolved in dimethyl sulphoxide (DMSO). There were no solvent Thirty male patients were recruited for this study. Inclusion criteria were 40-70 years old, plasma total cholesterol levels effects on platelet aggregation. There was no significant effect of the statins on platelet viability as analyzed above 6 
Platelet cholesterol and phospholipids content Platelet separation
For platelet studies, venous blood (40 ml) was collected Platelets from hypercholesterolaemic patients were washed three times with Hepes buffer, and then sonicated twice for through siliconized syringes into sodium citrate, 3.8% at a ratio of 951 (v5v) for platelet-rich plasma (PRP) preparation 20 s at 80 watt. Platelet lipids were extracted with hexane: isopropanol (352, v5v). The cholesterol content was or into acid citrate dextrose solution (1.4% citric acid, 2.5% sodium citrate, and 2% dextrose) at a ratio of 951 (v5v) for measured in the dried hexane phase by the method of Chiamori et al. [30] . Total platelet phospholipid content was washed platelets (WP) preparation. PRP was prepared by low-speed centrifugation (100 g for 10 min) at 25°C, and also determined in the dried hexane phase by the method of Rouser et al. [31] . Platelet protein was determined using the remaining sample was recentrifuged at 1000 g for 10 min to obtain platelet-poor plasma (PPP). Platelets in PRP were the method of Lowry et al. [32] . counted and diluted with PPP to achieve a uniform concentration of 3×10 8 at a level of less than 0.05 were considered significant. NaHCO 3 , and 5.5 mmol l −1 of glucose). For the preparation of WP suspension, 15 ml of acetic acid (1 mol l −1 ) were Results added to 1 ml of platelet suspension throughout WP preparation in order to ensure acidic conditions which are Effect of fluvastatin therapy on plasma lipids required for platelet resuspension. This procedure reduced the medium pH to 6.5 and it did not influence the Fluvastatin therapy in 25 patients (40 mg day −1 for a period of 24 weeks) resulted in 23% and 29% decrement in the aggregation response of the WP.
plasma levels of total cholesterol and LDL cholesterol, respectively ( Figure 1 ). This hypercholesterolaemic effect Platelet aggregation was achieved after 4 weeks of therapy ( Figure 1 ). Maximal decrement in plasma triglyceride levels (26%) was obtained Collagen (Nycomed Arzneimittel, Munchen, Germany) was used as the aggregating agent at a concentration of 4 mg ml (HDL) levels (1.15±0.11 and 1.18±0.10 mmol l −1 before and after 24 weeks of fluvastatin therapy respectively).
Effect of fluvastatin therapy on platelet aggregation and fluidity
Platelet aggregation was significantly ( P<0.02) reduced after 4 weeks of fluvastatin therapy by 6% and 10% as analyzed by determination of the maximal aggregation amplitude and the aggregation curve slope respectively (Figure 2a,b) . After 24 weeks of therapy a further significant reduction, by 11% and 15% respectively, was obtained content (92±3 vs 86±3 mg of phospholipids mg −1 cell protein before and after 24 weeks of fluvastatin therapy respectively). aggregation at all studied concentrations (Figure 3a) . Upon using washed platelets (WP), free of plasma constituents, the The in vitro effect of fluvastatin on platelet aggregation maximal inhibitory effects of fluvastatin and lovastatin on platelet aggregation was also obtained at 1 mg ml
All three studied statins, at a concentration of 0.01 mg ml −1 , had no effect on platelet aggregation (data not shown). At a (Figure 3b ). Maximal aggregation amplitude was inhibited by 16% or concentration of 0.1 mg ml −1 , fluvastatin inhibited platelet aggregation (in PRP) by 26% as determined by analysis of 11% for fluvastatin or lovastatin respectively (P<0.01) (Figure 3b ). Platelet aggregation slope also decreased, by the maximal aggregation amplitude (Figure 3a ). Lovastatin and pravastatin had no effect on aggregation at this low 24% and 14%, for fluvastatin and lovastatin respectively, whereas pravastatin, had no inhibitory effect on the platelet concentration. At 1.0 mg ml −1 , both fluvastatin and lovastatin had their maximal inhibitory effect on platelet aggregation aggregation slope (data not shown). PRP from hypercholesterolaemic patients exhibited a (Figure 3a) . At this concentration, fluvastatin and lovastatin inhibited maximal aggregation amplitude by 34% and 22% significant (P<0.01) increment of 14% in the aggregation curve slope in comparison to normal volunteers (Figure 4) . respectively (P<0.01). Pravastatin had no effect on platelet found to be 1.6 mg ml −1 ( Figure 5 , inset). Fluvastatin binding to platelets from normal subjects or from hypercholesterolaemic patients showed a similar dose-dependent pattern (Table 1) . Both nonlabelled fluvastatin and nonlabelled lovastatin substantially decreased the binding of the labelled fluvastatin to the platelets (by up to 80%), whereas pravastatin showed only minimal effect (Figure 6 ), suggesting that fluvastatin and lovastatin share similar platelet binding sites.
Fluvastatin binding to platelets

Discussion
Platelet activation is a risk factor for atherosclerosis, and thus reduction of the enhanced platelet aggregation in atherosclerotic patients is considered to be an important antiatherogenic intervention.
Fluvastatin concentration (mgml The present study demonstrates that fluvastatin therapy in The inhibitory effect of fluvastatin on platelet aggregation could be associated with the decrement in platelet cholesterol/phospholipid molar ratio, which parallelled the decUpon in vitro incubation of PRP from hypercholesterolaemic patients or from healthy control subjects, with fluvastatin rement in plasma cholesterol concentration. Increased platelet cholesterol content contributes to platelet activation (0.1 mg ml −1 ), the aggregation curve slope was decreased by 20% or by 30%, respectively (Figure 4) . in hypercholesterolaemic patients [33] , and this is related to aggregation [15] , reducing plasma LDL levels by statins therapy can be expected to reduce the platelets' tendency to aggregate. Indeed lipid lowering treatment in hypercholesterolaemic patients resulted in a substantial reduction in platelet aggregation [37] . Recently, it was shown that cholesterol lowering therapy using pravastatin reduced platelet thrombus formation and hence the risk of acute thrombosis and coronary events in hypercholesterolaemic patients [38] . In the present study the inhibitory effect of fluvastatin on platelet aggregation increased with time beyond the first 4 weeks of therapy even though there was no further decrement in platelet cholesterol/phospholipids molar ratio. This may be the result of the reduction (by 26%) of plasma triglycerides levels after 8 weeks of drug , which are comparable with the in vivo drug concentration in the plasma.
The peak concentration (C max ) of fluvastatin in the plasma the effect of platelet cholesterol on the interaction between after multiple doses is about 0.4 mg ml −1 [39] . Unlike platelets and the aggregating agents. Hochgraf et al. [28] fluvastatin, lovastatin was less potent at this concentration; the found that in hypercholesterolaemic patients, lovastatin C max of lovastatin in plasma is as low as 0.07 mg ml −1 [40] . therapy attenuates the increased platelet cholesterol/phosFluvastatin and pravastatin are used in their active hydroxy pholipid molar ratio and reduced the increased platelet acid forms, whereas lovastatin is used as an inactive lactone. aggregatory response in these patients to normal values. It
This inactive lactone form of lovastatin is converted to its seems reasonable to postulate that fluvastatin increased active form (b-hydroxy acid) in the liver by the enzyme platelet fluidity, which also affects platelet aggregation, by lactonase [41] . In the present study we compared fluvastatin reducing platelet cholesterol/phospholipid molar ratio.
to the inactive form of lovastatin and demonstrated a direct Plasma LDL, and more so oxidatively modified LDL, triggers inhibitory effect in vitro of both drugs on platelet activation. platelet activation and enhances platelet aggregation and
The inhibitory in vitro effects of fluvastatin and lovastatin secretion via specific binding sites for the lipoprotein on the on platelet aggregation was more prominent in PRP than platelet surface which differ from the classical apolipoprotein in WP. This may be due to an effect of plasma constituents B/E receptors on fibroblasts [15, [34] [35] [36] .
which can influence the interaction between the statin and As plasma LDL has been shown to increase platelet 
